The progression of Alzheimer’s disease through different stages of impairment is increasingly recognized by experts in the field. Bradford Dickerson, MD from Massachusetts General Hospital / Harvard Medical School, Boston, MA speaks to us about the ways in which this progression can be considered to personalize clinical trials to patients, and the effect this could have on patient care and research. This interview was recorded at the 2017 Alzheimer’s Association International Conference (AAIC) in London, UK.
